Literature DB >> 12634961

CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET.

D Visvikis1, D C Costa, I Croasdale, A H R Lonn, J Bomanji, S Gacinovic, P J Ell.   

Abstract

The introduction of combined PET/CT systems has a number of advantages, including the utilisation of CT images for PET attenuation correction (AC). The potential advantage compared with existing methodology is less noisy transmission maps within shorter times of acquisition. The objective of our investigation was to assess the accuracy of CT attenuation correction (CTAC) and to study resulting bias and signal to noise ratio (SNR) in image-derived semi-quantitative uptake indices. A combined PET/CT system (GE Discovery LS) was used. Different size phantoms containing variable density components were used to assess the inherent accuracy of a bilinear transformation in the conversion of CT images to 511 keV attenuation maps. This was followed by a phantom study simulating tumour imaging conditions, with a tumour to background ratio of 5:1. An additional variable was the inclusion of contrast agent at different concentration levels. A CT scan was carried out followed by 5 min emission with 1-h and 3-min transmission frames. Clinical data were acquired in 50 patients, who had a CT scan under normal breathing conditions (CTAC(nb)) or under breath-hold with inspiration (CTAC(insp)) or expiration (CTAC(exp)), followed by a PET scan of 5 and 3 min per bed position for the emission and transmission scans respectively. Phantom and patient studies were reconstructed using segmented AC (SAC) and CTAC. In addition, measured AC (MAC) was performed for the phantom study using the 1-h transmission frame. Comparing the attenuation coefficients obtained using the CT- and the rod source-based attenuation maps, differences of 3% and <6% were recorded before and after segmentation of the measured transmission maps. Differences of up to 6% and 8% were found in the average count density (SUV(avg)) between the phantom images reconstructed with MAC and those reconstructed with CTAC and SAC respectively. In the case of CTAC, the difference increased up to 27% with the presence of contrast agent. The presence of metallic implants led to underestimation in the surrounding SUV(avg) and increasing non-uniformity in the proximity of the implant. The patient study revealed no statistically significant differences in the SUV(avg) between either CTAC(nb) or CTAC(exp) and SAC-reconstructed images. The larger differences were recorded in the lung. Both the phantom and the patient studies revealed an average increase of approximately 25% in the SNR for the CTAC-reconstructed emission images compared with the SAC-reconstructed images. In conclusion, CTAC(nb) or CTAC(exp) is a viable alternative to SAC for whole-body studies. With CTAC, careful consideration should be given to interpretation of images and use of SUVs in the presence of oral contrast and in the proximity of metallic implants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12634961     DOI: 10.1007/s00259-002-1070-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  16 in total

1.  Iterative deblurring for CT metal artifact reduction.

Authors:  G Wang; D L Snyder; J A O'Sullivan; M W Vannier
Journal:  IEEE Trans Med Imaging       Date:  1996       Impact factor: 10.048

2.  A segmented attenuation correction for PET.

Authors:  E Z Xu; N A Mullani; K L Gould; W L Anderson
Journal:  J Nucl Med       Date:  1991-01       Impact factor: 10.057

3.  Attenuation correction for a combined 3D PET/CT scanner.

Authors:  P E Kinahan; D W Townsend; T Beyer; D Sashin
Journal:  Med Phys       Date:  1998-10       Impact factor: 4.071

4.  Epoxy resin based tissue substitutes.

Authors:  D R White; R J Martin; R Darlison
Journal:  Br J Radiol       Date:  1977-11       Impact factor: 3.039

5.  Attenuation correction using count-limited transmission data in positron emission tomography.

Authors:  S R Meikle; M Dahlbom; S R Cherry
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

6.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

8.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

Authors:  R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

9.  PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients.

Authors:  C Burger; G Goerres; S Schoenes; A Buck; A H R Lonn; G K Von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-19       Impact factor: 9.236

10.  PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images.

Authors:  Yuji Nakamoto; Medhat Osman; Christian Cohade; Laura T Marshall; Jonathan M Links; Steve Kohlmyer; Richard L Wahl
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057

View more
  31 in total

Review 1.  Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives.

Authors:  D Visvikis; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

2.  Clinical evaluation of a breathing protocol for PET/CT.

Authors:  Ramon de Juan; Burkhardt Seifert; Thomas Berthold; Gustav K von Schulthess; Gerhard W Goerres
Journal:  Eur Radiol       Date:  2003-12-16       Impact factor: 5.315

3.  The new-generation positron emission tomography/computed tomography scanners: implications for cardiac imaging.

Authors:  Stephen L Bacharach
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

4.  Evaluation of a 3D local multiresolution algorithm for the correction of partial volume effects in positron emission tomography.

Authors:  Adrien Le Pogam; Mathieu Hatt; Patrice Descourt; Nicolas Boussion; Charalampos Tsoumpas; Federico E Turkheimer; Caroline Prunier-Aesch; Jean-Louis Baulieu; Denis Guilloteau; Dimitris Visvikis
Journal:  Med Phys       Date:  2011-09       Impact factor: 4.071

5.  Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements.

Authors:  Tira Bunyaviroch; Timothy G Turkington; Terence Z Wong; John W Wilson; James G Colsher; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2007-12-21       Impact factor: 3.488

6.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

7.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.

Authors:  D L Francis; D Visvikis; D C Costa; T H A Arulampalam; C Townsend; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

8.  Positron emission tomography (PET) attenuation correction artefacts in PET/CT and PET/MRI.

Authors:  C Buchbender; V Hartung-Knemeyer; M Forsting; G Antoch; T A Heusner
Journal:  Br J Radiol       Date:  2013-05       Impact factor: 3.039

9.  [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

Authors:  Victoria S Warbey; Rosalie E Ferner; Joel T Dunn; Eduardo Calonje; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

Review 10.  Methodological considerations in quantification of oncological FDG PET studies.

Authors:  Dennis Vriens; Eric P Visser; Lioe-Fee de Geus-Oei; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.